Avantor Inc. (AVTR)
NYSE: AVTRIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVTR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $10.06B
- P/E (TTM)
- 29.68
- Forward P/E
- 16.73
- EPS (TTM)
- $0.50
- Dividend yield
- None
- 52-week range
- 7.27 – 17.45
- Day range
- 14.80 – 15.50
- Volume / Avg
- 12.25M / 8.77M
- Beta
- —
- Shares outstanding
- 677.62M
52-week range
AVTR stock today
On Nov 20, AVTR ended the session at $14.84, shedding $0.28 (1.85%), versus the S&P 500's 3.70% decline. Shares are 15.0% below their 52-week high of $17.45, set on Oct 22, 2026 and 104.3% above the 52-week low of $7.27, in the middle of the past year's range. AVTR is up 29.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 28.8%.
Avantor trades at 29.7x its trailing twelve-month earnings per share of $0.50. Its forward P/E of 16.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Avantor
Company profileAvantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Mr. Emmanuel Ligner
- Headquarters
- Radnor, PA
- Employees
- 13,500
- IPO year
- 2019
- Website
- avantorsciences.com
Financial highlights
Full financialsIn fiscal 2025, Avantor generated $6.55 billion in revenue, down 3.4% from fiscal 2024, its first annual decline since 2024. Avantor reported a net loss of $530.2 million, compared with net income of $711.5 million a year earlier. Gross margin was 32.7% (down from 33.6%) and operating margin -3.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $6.55B | $6.78B | $6.97B | $7.51B | $7.39B |
| Growth | -3.41% | -2.64% | -7.26% | +1.71% | +15.52% |
| Net income | $-530.20M | $711.50M | $321.10M | $686.50M | $572.60M |
| EPS (diluted) | $-0.78 | $1.04 | $0.47 | $1.01 | $0.85 |
Analyst forecast
ForecastConsensus (15 analysts)
hold
Avg. price target
$17.35+16.91%
- Strong buy 0
- Buy 2
- Hold 12
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 28, 2026
- EPS actual vs est.
- $0.30 vs $0.21
- Surprise
- +42.86%
AVTR news
All AVTR news- Avantor: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Avantor Consensus Price Target Increased by 10.49% to $17.25Nasdaq
- Avantor, Inc. (AVTR) is a Great Momentum Stock: Should You Buy?Nasdaq
- Avantor (AVTR) Upgraded to Buy: What Does It Mean for the Stock?Nasdaq
- Is Avantor (AVTR) Stock Outpacing Its Medical Peers This Year?NasdaqAVTR, NVS
- Avantor forecasts 0.75% to 1.25% 2026 organic revenue growth as it targets net leverage below 3x by year-endSeeking Alpha
- Avantor, Inc. (AVTR) Q3 2026 Earnings Call TranscriptSeeking Alpha
- Avantor, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
Avantor peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIOBio-Rad Laboratories Inc. Class A | 358.90 | -2.34% | $9.65B | vs AVTR |
| BRKRBruker Corporation | 56.46 | -9.08% | $8.62B | vs AVTR |
| TXG10x Genomics Inc. Class A | 51.80 | -9.72% | $6.81B | vs AVTR |
| RVTYRevvity Inc. | 145.22 | -4.20% | $16.21B | vs AVTR |
| ALMRAlamar Biosciences Inc. | 26.48 | -7.67% | $1.84B | vs AVTR |
| CTKBCytek Biosciences Inc. | 6.12 | -3.16% | $800.40M | vs AVTR |
| PACBPacific Biosciences of California Inc. | 1.63 | -7.39% | $508.95M | vs AVTR |
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs AVTR |
Indexes, lists and sector
Avantor stock FAQ
What is Avantor's stock price today?
AVTR last traded at $14.84 as of Nov 20, 4:00 PM EST, down 1.85% on the day. Prices are delayed at least 15 minutes.
What is AVTR's P/E ratio?
AVTR trades at a trailing P/E ratio of 29.68 and a forward P/E of 16.73.
Who is Avantor's CEO?
Mr. Emmanuel Ligner is the chief executive officer of Avantor Inc., which has about 13,500 employees.
What is the AVTR 52-week high?
The 52-week high for AVTR is $17.45 and the 52-week low is $7.27. The stock is currently 15.0% below its high.